JNJ-5957

Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results
Motley Fool
Tue, 05/19/20 - 11:30 pm
JNJ
Multiple Myeloma
bispecific antibodies
JNJ-5957
teclistamab
clinical trials